POCARED Diagnostics Secures $50 Million Capital Commitment From GEM as Company envisages going public via SPAC merger
POCARED will control the timing and maximum amount of drawdowns under this facility and has no minimum drawdown obligation.
- POCARED will control the timing and maximum amount of drawdowns under this facility and has no minimum drawdown obligation.
- Concurrent with a public listing of POCARED's shares, POCARED will issue warrants to GEM to purchase up to 5% of the common stock of the company.
- POCARED Diagnostics Ltd (POCARED) is on the verge of revolutionizing infectious disease diagnosis by introducing the world's fastest time to results.
- "This GEM Group investment and funding will enable our talented and dedicated POCARED team to realize their ultimate goal of transforming Infectious Disease Diagnostics.